A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future - Moore, Kristine A.; Ostrowsky, Julia T.; Kraigsley, Alison M.; Mehr, Angela J.; Bresee, Joseph S.; Friede, Martin H.; Gellin, Bruce G.; Golding, Josephine P.; Hart, Peter J.; Moen, Ann; Weller, Charlotte L.; Osterholm, Michael T.; et al. (Vaccine, 2021)
Keywords: Allergy and Immunology; Animals; Broadly protective influenza vaccines; Collaboration; Consortia; Coronaviruses; COVID-19 vaccines; finance; human influenza; Humans; Immunology; Infectious diseases; Influenza; Influenza Vaccines; Influenza, Human - epidemiology; Influenza, Human - prevention & control; issues and policy; Medical research; Orthomyxoviridae; Orthomyxoviridae Infections; Pandemic preparedness; Pandemics; Public health; R&D; Regulation; Research & development; research and development; Roadmap; Seasonal influenza vaccines; Severe acute respiratory syndrome coronavirus 2; Stakeholders; Universal influenza vaccines; vaccine development; Vaccines; Virology; Viruses; LAIV; CEPI; IVR; Universal influenza vaccines; Seasonal influenza vaccines; COBRA; ABS; HVAC; CARB-X; ME&A; CIDRAP; FVVA; CHIVIM; ADCC; WHO; CIVICs; SME; LMICs; NIAID; EU; HAI; R&D; Broadly protective influenza vaccines; Roadmap; ACT; NA; Influenza; IIV; GISRS; HA; Pandemic preparedness; US National Institute of Allergy and Infectious Diseases; hemagglutinin; inactivated influenza vaccines; heating, ventilation, and air conditioning; computationally optimized broadly reactive antigen; biopharmaceutical accelerator for combating antibiotic resistant bacteria; World Health Organization; Global Influenza Surveillance and Response System; antibody-dependent cellular cytotoxicity; neuraminidase; Collaborative Influenza Vaccine Innovation Centers; Research and Development; Access to COVID-19 Tools; controlled human influenza virus infection model; Center for Infectious Disease Research and Policy; live-attenuated influenza vaccines; monitoring, evaluation, and adjustment; Access and Benefit Sharing; low- and middle-income countries; full value of vaccine assessment; subject matter expert; Influenza Vaccines Research and Development (R&D) Roadmap; European Union; Coalition for Epidemic Preparedness Innovations; hemagglutination-inhibition